MedTrace Logo

MSC Intratissular Injection in Crohn Disease Patients

NCT03901235 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-12-12

No results posted yet for this study

Summary

The main objective is to assess the efficacy of local injection of MSC on the healing of refractory intestinal and perianal lesions in crohn disease. The second co-primary endpoint is safety.

Conditions

  • Efficacy and Safety

Interventions

BIOLOGICAL

Mesenchymal Stromal Cells

Suspension of mesenchymal stromal cells for intratissular injection

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Liege

    collaborator OTHER

  • University of Liege

    lead OTHER

Principal Investigators

  • Edouard Louis, Prof · Centre Hospitalier Universitaire de Liege

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-15
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03901235 on ClinicalTrials.gov